Current Research Goals:
To determine the role of contact activation in acute intraluminal thrombus propagation using synthetic vascular grafts in a primate model of thrombosis and hemostasis. If the functionality of the contact system enzyme complex (FXI/FXII/KK/HMWK) is relevant to the pathogenesis of thrombosis, a FXI inhibitor could become the first safe antithrombotic agent.
To characterize the effects of endogenous protein C activation on acute arterial thrombogenesis and hemostasis using rationally engineered recombinant enzymes. A pharmacologically viable protein C activator could help utilize the body's own antithrombotic and antiinflammatory system similar to the way streptokinase and tPA became useful fibrinolysis activators.
Baboon blood was collected into 3.2% sodium citrate anticoagulant (9:1, v/v). Platelet-rich plasma was prepared and frozen at −80°C.
Interfaced with a NuQuest InteCam computer system.
"The HEMAVET® provides superior cell separation for accurate and precise analysis through use of patented Focused Flow Technology (eleven patents issued) thus giving the best technology available for dealing with veterinary samples. In addition patented Expectation Maximization software helps categorize the different types of cells."
The SpectroMax 340 "mimics a dual beam spectrophotometer, measures each sample in the plate directly, and eliminates measurement error due to variations in light output between optical fibers on other instruments for more reliable data reporting. The eight-channel system delivers both high precision and speed when reading 96- and 384-well microplates for endpoint measurements, kinetic assays, and spectral scans."
"The FXI-/- genotype was backcrossed onto the C57BL/6 background for >9 generations."
Model used to study thrombosis formation in mouse models. Thrombus formation induced by ferric chloride or laser injury.
Model is used to study the role of anticoagulation in the treatment of sepsis-associated consumptive coagulopathy.
"Clone 14E11 was expanded in a CL1000 bioreactor (Integra Biosciences), and immunoglobulin G (IgG) was purified by cation exchange and thiophilic agarose chromatography. 14E11 was biotinylated using an EZ-link sulfo-NHS-biotinylation kit (Thermo Scientific)."
Antibody binds to the A3 domain of human fXI and interferes with activation of factor IX by fXIa.